Brain metastases treated with hypofractionated stereotactic radiotherapy: 8 years experience after Cyberknife installation.

Date publication

avril 2020

Journal

Radiation oncology (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie

Tous les auteurs :
Mengue L, Bertaut A, Ngo Mbus L, Doré M, Ayadi M, Clément-Colmou K, Claude L, Carrie C, Laude C, Tanguy R, Blanc J, Sunyach MP

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32303236

Résumé

Hypofractionated stereotactic radiotherapy (HFSRT) is indicated for large brain metastases (BM) or proximity to critical organs (brainstem, chiasm, optic nerves, hippocampus). The primary aim of this study was to assess factors influencing BM local control after HFSRT. Then the effect of surgery plus HFSRT was compared with exclusive HFSRT on oncologic outcomes, including overall survival.

Mots clés

Brain metastases, Hypofractionated stereotactic radiotherapy, Radionecrosis

Référence

Radiat Oncol. 2020 Apr 17;15(1):82